Page 15 - Flipbook
P. 15

A phase 3 trial with a 2x2 factorial design of abiraterone acetate plus prednisone and/or local radiotherapy in men with de novo metastatic castration-sensitive prostate cancer
                                         (mCSPC): <br />first results of PEACE-1
   10   11   12   13   14   15   16   17   18   19   20